Table 1.
Baseline characteristics in CHD patients with T2DM.
| Characteristics | Total |
Baseline HbA1c < 7 % |
Baseline HbA1c ≥ 7 % |
P value |
|---|---|---|---|---|
| N = 6839 | N = 3023 | N = 3816 | ||
| Demographics | ||||
| Age, years | 61.8 ± 10.0 | 61.7 ± 10.2 | 61.8 ± 9.9 | 0.876 |
| Male sex, n (%) | 4932 (72.1) | 2273 (75.2) | 2659 (69.7) | <0.001 |
| BMI, kg/m2 | 26.1 ± 3.3 | 25.9 ± 3.2 | 26.4 ± 3.3 | <0.001 |
| Duration of T2DM | 9.5 ± 7.1 | 8.7 ± 6.9 | 10.2 ± 7.2 | <0.001 |
| Diagnosis on admission, n (%) | ||||
| ACS | 2901 (42.4) | 1116 (36.9) | 1785 (46.8) | <0.001 |
| STEMI | 1556 (22.8) | 596 (19.7) | 960 (25.2) | <0.001 |
| NSTEMI | 710 (10.4) | 297 (9.8) | 413 (10.8) | 0.179 |
| UAP | 635 (9.3) | 223 (7.4) | 412 (10.8) | <0.001 |
| SAP | 3938 (57.6) | 1907 (63.1) | 2031 (53.2) | <0.001 |
| Medical history, n (%) | ||||
| Current Smoking | 1272 (18.6) | 432 (14.3) | 840 (22.0) | <0.001 |
| Hypertension | 4813 (70.4) | 2192 (72.5) | 2621 (68.7) | 0.001 |
| Dyslipidemia | 5361 (78.4) | 2460 (81.4) | 2901 (76.0) | <0.001 |
| CKD | 202 (3.0) | 92 (3.0) | 110 (2.9) | 0.697 |
| COPD | 94 (1.4) | 50 (1.7) | 44 (1.2) | 0.077 |
| Prior stroke | 1227 (17.9) | 543 (18.0) | 684 (17.9) | 0.968 |
| Prior MI | 1352 (19.8) | 538 (17.8) | 814 (21.3) | <0.001 |
| Prior PCI | 1952 (28.5) | 889 (29.4) | 1063 (27.9) | 0.158 |
| Prior CABG | 213 (3.1) | 101 (3.3) | 112 (2.9) | 0.337 |
| PAD | 456 (6.7) | 212 (7.0) | 244 (6.4) | 0.308 |
| Laboratory variables | ||||
| HbA1c, % | 7.4 ± 1.5 | 6.2 ± 0.5 | 8.4 ± 1.3 | <0.001 |
| FBG, mmol/L | 8.0 ± 3.3 | 6.4 ± 2.2 | 9.4 ± 3.5 | <0.001 |
| SCR, mmol/L | 84.0 ± 32.6 | 84.9 ± 40.9 | 83.2 ± 24.1 | 0.034 |
| hs-CRP, mg/L | 3.9 ± 5.6 | 3.4 ± 5.7 | 4.3 ± 5.6 | <0.001 |
| LVEF, % | 59.3 ± 8.2 | 59.9 ± 7.8 | 58.9 ± 8.5 | <0.001 |
| Medications, n (%) | ||||
| Insulin | 1635 (23.9) | 278 (9.2) | 1393 (36.5) | <0.001 |
| Lipid-lowering drugs | 6532 (95.9) | 2882 (95.6) | 3650 (96.1) | 0.374 |
| ACEI/ARB | 3886 (57.0) | 1727 (57.3) | 2159 (56.8) | 0.689 |
| CCB | 3046 (44.7) | 1467 (48.7) | 1579 (41.6) | <0.001 |
| β-blocker | 5517 (81.0) | 2461 (81.7) | 3056 (80.4) | 0.199 |
| aspirin | 6544 (96.0) | 2878 (95.5) | 3666 (96.5) | 0.038 |
| P2Y12 antagonist | 6515 (95.6) | 2951 (97.9) | 3564 (93.8) | <0.001 |
CHD, coronary heart disease; T2DM, type2 diabetes mellitus; HbA1c, glycosylated hemoglobin; BMI, Body mass index; ACS, acute coronary syndrome; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; UAP, unstable angina pectoris; SAP, stable angina pectoris; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; PAD, peripheral artery disease; FBG, fasting blood glucose; SCR, serum creatinine; hs-CRP, high sensitive-C reaction protein; LVEF, left ventricular ejection fraction; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor antagonists; CCB, calcium channel blocker; P2Y12 antagonist, P2Y12 receptor antagonist.